Dutasteride for the Treatment of Prostate Cancer

Video

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses the mechanism of action of dutasteride and its role in a phase II prostate cancer trial.

Clinical Pearls

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses the mechanism of action of dutasteride and its role in a phase II prostate cancer trial.

  • Dutasteride is a dual 5-α reductase inhibitor that prevents the conversion of testosterone to DHT. It is classically used for people with benign prostatic hypertrophy.
  • In a phase II trial, dutasteride was combined with abiraterone acetate for the treatment of metastatic castration resistant prostate cancer.
Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Related Content